147 related articles for article (PubMed ID: 34946600)
1. Enriching the Arsenal of Pharmacological Tools against MICAL2.
Barravecchia I; Barresi E; Russo C; Scebba F; De Cesari C; Mignucci V; De Luca D; Salerno S; La Pietra V; Giustiniano M; Pelliccia S; Brancaccio D; Donati G; Da Settimo F; Taliani S; Angeloni D; Marinelli L
Molecules; 2021 Dec; 26(24):. PubMed ID: 34946600
[TBL] [Abstract][Full Text] [Related]
2. MICAL2 is expressed in cancer associated neo-angiogenic capillary endothelia and it is required for endothelial cell viability, motility and VEGF response.
Barravecchia I; Mariotti S; Pucci A; Scebba F; De Cesari C; Bicciato S; Tagliafico E; Tenedini E; Vindigni C; Cecchini M; Berti G; Vitiello M; Poliseno L; Mazzanti CM; Angeloni D
Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2111-2124. PubMed ID: 31004710
[TBL] [Abstract][Full Text] [Related]
3. MICAL2 is a novel human cancer gene controlling mesenchymal to epithelial transition involved in cancer growth and invasion.
Mariotti S; Barravecchia I; Vindigni C; Pucci A; Balsamo M; Libro R; Senchenko V; Dmitriev A; Jacchetti E; Cecchini M; Roviello F; Lai M; Broccoli V; Andreazzoli M; Mazzanti CM; Angeloni D
Oncotarget; 2016 Jan; 7(2):1808-25. PubMed ID: 26689989
[TBL] [Abstract][Full Text] [Related]
4. MICAL2 promotes breast cancer cell migration by maintaining epidermal growth factor receptor (EGFR) stability and EGFR/P38 signalling activation.
Wang Y; Deng W; Zhang Y; Sun S; Zhao S; Chen Y; Zhao X; Liu L; Du J
Acta Physiol (Oxf); 2018 Feb; 222(2):. PubMed ID: 28719045
[TBL] [Abstract][Full Text] [Related]
5. miR-205-5p suppresses pulmonary vascular smooth muscle cell proliferation by targeting MICAL2-mediated Erk1/2 signaling.
Tao W; Sun W; Zhu H; Zhang J
Microvasc Res; 2019 Jul; 124():43-50. PubMed ID: 30853343
[TBL] [Abstract][Full Text] [Related]
6. MICAL2 contributes to gastric cancer cell migration via Cdc42-dependent activation of E-cadherin/β-catenin signaling pathway.
Wang Q; Qi C; Min P; Wang Y; Ye F; Xia T; Zhang Y; Du J
Cell Commun Signal; 2022 Sep; 20(1):136. PubMed ID: 36064550
[TBL] [Abstract][Full Text] [Related]
7. MICAL2 is a novel nucleocytoplasmic shuttling protein promoting cancer invasion and growth of lung adenocarcinoma.
Zhou W; Liu Y; Gao Y; Cheng Y; Chang R; Li X; Zhou Y; Wang S; Liang L; Duan C; Zhang C
Cancer Lett; 2020 Jul; 483():75-86. PubMed ID: 32360180
[TBL] [Abstract][Full Text] [Related]
8. MICAL2 Contributes to Gastric Cancer Cell Proliferation by Promoting YAP Dephosphorylation and Nuclear Translocation.
Qi C; Min P; Wang Q; Wang Y; Song Y; Zhang Y; Bibi M; Du J
Oxid Med Cell Longev; 2021; 2021():9955717. PubMed ID: 34650666
[TBL] [Abstract][Full Text] [Related]
9. MICAL2 Mediates p53 Ubiquitin Degradation through Oxidating p53 Methionine 40 and 160 and Promotes Colorectal Cancer Malignance.
Lu J; Li Y; Wu Y; Zhou S; Duan C; Dong Z; Kang T; Tang F
Theranostics; 2018; 8(19):5289-5306. PubMed ID: 30555547
[TBL] [Abstract][Full Text] [Related]
10. Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high Gleason score and prostate cancer progression.
Ashida S; Furihata M; Katagiri T; Tamura K; Anazawa Y; Yoshioka H; Miki T; Fujioka T; Shuin T; Nakamura Y; Nakagawa H
Clin Cancer Res; 2006 May; 12(9):2767-73. PubMed ID: 16675569
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of MICAL2, a novel tumor-promoting factor, accelerates tumor progression through regulating cell proliferation and EMT.
Cai Y; Lu J; Tang F
J Cancer; 2018; 9(3):521-527. PubMed ID: 29483957
[TBL] [Abstract][Full Text] [Related]
12. Stereospecific Inhibitory Effects of CCG-1423 on the Cellular Events Mediated by Myocardin-Related Transcription Factor A.
Watanabe B; Minami S; Ishida H; Yoshioka R; Nakagawa Y; Morita T; Hayashi K
PLoS One; 2015; 10(8):e0136242. PubMed ID: 26295164
[TBL] [Abstract][Full Text] [Related]
13. A unique small molecule inhibitor of enolase clarifies its role in fundamental biological processes.
Jung DW; Kim WH; Park SH; Lee J; Kim J; Su D; Ha HH; Chang YT; Williams DR
ACS Chem Biol; 2013; 8(6):1271-82. PubMed ID: 23547795
[TBL] [Abstract][Full Text] [Related]
14. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling.
Evelyn CR; Wade SM; Wang Q; Wu M; Iñiguez-Lluhí JA; Merajver SD; Neubig RR
Mol Cancer Ther; 2007 Aug; 6(8):2249-60. PubMed ID: 17699722
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of MICAL2 by ARG promotes head and neck cancer tumorigenesis by regulating skeletal rearrangement.
Zhang Z; Liu R; Wang Y; Wang Y; Shuai Y; Ke C; Jin R; Wang X; Luo J
Oncogene; 2022 Jan; 41(3):334-346. PubMed ID: 34750518
[TBL] [Abstract][Full Text] [Related]
16. Differential regulation of actin microfilaments by human MICAL proteins.
Giridharan SS; Rohn JL; Naslavsky N; Caplan S
J Cell Sci; 2012 Feb; 125(Pt 3):614-24. PubMed ID: 22331357
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological intervention of MKL/SRF signaling by CCG-1423 impedes endothelial cell migration and angiogenesis.
Gau D; Veon W; Capasso TL; Bottcher R; Shroff S; Roman BL; Roy P
Angiogenesis; 2017 Nov; 20(4):663-672. PubMed ID: 28638990
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and structure-activity relationships of novel, potent, orally active hypoxia-inducible factor-1 inhibitors.
Nagao S; Yamane Y; Funasaka S; Tanaka K; Miyazaki K; Kotake Y; Kamata J; Watanabe-Miyano S; Toyama O; Ozawa Y; Mizui Y; Okamoto K; Ito D
Bioorg Med Chem; 2014 Oct; 22(19):5513-29. PubMed ID: 25139751
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of benzoisothiazolones as selective inhibitors of PHOSPHO1.
Bravo Y; Teriete P; Dhanya RP; Dahl R; Lee PS; Kiffer-Moreira T; Ganji SR; Sergienko E; Smith LH; Farquharson C; Millán JL; Cosford ND
Bioorg Med Chem Lett; 2014 Sep; 24(17):4308-11. PubMed ID: 25124115
[TBL] [Abstract][Full Text] [Related]
20. A novel oncogenic seRNA promotes nasopharyngeal carcinoma metastasis.
Tan Y; Jiang C; Jia Q; Wang J; Huang G; Tang F
Cell Death Dis; 2022 Apr; 13(4):401. PubMed ID: 35461306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
